{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 'DOCUMENT HISTORY', 'Document', 'Date', 'Amendment 2', '25 Oct 2019', 'Amendment 1.2 (France)', '14 Oct 2019', 'Amendment 1.1 (Germany)', '27 Jun 2019', 'Amendment 1', '11 Dec 2018', 'Original Protocol', '16 Nov 2018', 'Amendment 2 (25 Oct 2019)', 'This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of', 'Directive 2001/20/EC of the European Parliament and the Council of the European Union.', 'Overall Rationale for the Amendment', 'To revise secondary and exploratory endpoints, to decrease burden to patients by reduction in', 'assessment and visit frequency, to provide additional guidance for supplemental dosing, and to', 'clarify minor operational aspects of the protocol.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Title page', 'Updated legal registered address.', 'Sponsor Signatory', \"Removed sponsor signatory's personal contact\", 'Contact information is', 'information.', 'provided in the study contact', 'list provided to sites.', 'Section 1.1 and Section 3', 'Moved change from baseline in MG-QOL15r', 'To better characterize disease', 'Objectives and Endpoints', 'and Neuro-QOL Fatigue scores and MG-ADL', 'parameters associated with', 'and QMG responder from exploratory to', 'gMG and yield a clearer', 'secondary endpoints. PK/PD/ADA endpoints', 'assessment of the impact of', 'moved from under exploratory to new', 'study intervention.', 'independent subheading. Expanded', 'exploratory endpoints to include change from', 'baseline in MG-ADL and QMG', 'subcomponent scores as well as incidence of', 'hospitalizations/MG-related hospitalizations', 'and Clinical Deterioration/MG crisis. Clarified', 'that endpoints will be evaluated throughout', 'study.', 'Section 1.3 Schedule of', 'Removed evaluation of Myasthenia Gravis', 'Post-intervention status', 'Activities', 'Foundation of America-Post-Interventional', 'cannot be evaluated before', 'Status (MGFAPIS) on Day 1.', 'patients receive study', 'intervention.', 'Added serum pregnancy test at Day 183/ET.', 'To ensure patient safety.', 'Removed visits at Weeks 3, 8, 14, 22, and 40;', 'To reduce burden on patient.', 'reduced number of visits at which MG-', 'QOL15r, Neuro-QOL Fatigue, and EQ-5D-5L', 'are collected, including removal from Clinical', 'Deterioration visits; expanded visit window', 'and reduced/moved PK/Free C5 and ADA', 'collections during extension.', 'Page 4 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Added body weight collection at all visits.', 'Needed to ensure that proper', 'dosage is administered.', 'Revised footnotes to specify data collected for', 'Clarifications', 'MG history and C-SSRS, assessments needed', 'at Clinical Deterioration visits, and', 'requirement for Properly Trained Clinical', 'Evaluator to perform QMC and MGC', 'assessments.', 'Section 2.3 Study Rationale', 'Added approval of eculizumab for the', 'Update.', 'treatment of neuromyelitis optica spectrum', 'disorder.', 'Section 4.1.1 Screening Period', 'Clarified MG history data collection,', 'To enable assessment of pre-', 'including 2-year hospitalization history.', 'study hospitalizations.', 'Removed incorrect statement about retaining a', 'Correction.', 'patient who experiences Clinical', 'Deterioration/MG crisis during the Screening', 'Period (inconsistent with Section 5.4).', 'Section 4.2.4 Responsibilities', 'Noted that MG-ADL must be performed first,', 'Clarification.', 'for Myasthenia Gravis', 'QMG second.', 'Assessments', 'Section 4.4 Justification for', 'Revised to reflect that the ravulizumab dosing', 'To inform on labeled dosing', 'Dose', 'regimen used in this study is approved for', 'recommendation.', 'adult patients with PNH.', 'Section 5.1 Inclusion Criteria', 'Revised IC#2 and IC#3 to clarify that MG', 'To further clarify entry', 'diagnosis must occur at least 6 months prior to', 'criteria for the investigator.', 'screening, and that eligibility is confirmed by', 'positive anti-AChR Ab test result at screening', 'and by abnormal neuromuscular transmission', 'test and/or improvement in MG signs with', 'oral cholinesterase inhibitor treatment either', 'historically or during screening.', 'Section 5.2 Exclusion Criteria', 'Revised EC#1 to permit treated patients with', 'To clarify entry criteria for', 'stage 1 or 2 thymoma other than thymic', 'patients with thymoma.', 'carcinoma and EC#2 to exclude', 'thymomectomy or any thymic surgery.', 'Added 3 new exclusion criteria for history of', 'To exclude enrollment of', 'unexplained infections, active infections', 'patients with active systemic', 'within 14 days of study drug administration,', 'infections.', 'or fever within 7 days of study drug', 'administration.', 'Section 6.1 Study Drug', 'Added instruction for action to be taken if a', 'Clarification.', 'Administration', \"patient's body weight drops below 40 kg\", 'during treatment.', 'Section 6.4 Concomitant', 'Added that MG-specific medication or therapy', 'Clarification regarding data', 'Therapy', '(eg, thymectomy, ISTs including', 'collection.', 'corticosteroids, IVIg, and PE/PP) within 2', 'years prior to screening will be recorded.', 'Page 5 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}